CY
Insider
Catriona Yale
Chief Development OfficerCatriona Yale (Chief Development Officer) filed 12 Form 4 reports in the past 24 months (0 purchases, 12 sales, 4 filed past the two-business-day deadline), most often in AKRO. The largest single filing was $3.0M of AKRO (53,590 sh across 3 lots, as filed), executed Jan 27 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
12
0 buys · 12 sells · 4 late
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$8.6M
shares × price, as filed
Last traded
Jul 16 2025
Filed Jul 18 2025
Volume by month
Buys $0
Sells $8.6M
Shares × price, as filed · by filing month · past 24 months
Most traded names
AKRO
AKRO
0 buys · 12 sells
12 filings
Recent filings
AKROSALE
Akero Therapeutics, Inc.
View filing →
$458K8,658 sh × $52.87
Exec Jul 16 2025
Filed Jul 18 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $493K
9,105 sh across 2 lots
Exec Jun 16 2025
Filed Jun 20 2025 · 5:30 PM ET † AKROSALE Akero Therapeutics, Inc. View filing → $151K
2,803 sh × $54.00
Exec Jun 10 2025
Filed Jun 12 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $393K
10,000 sh across 3 lots
Exec May 15 2025
Filed May 19 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $298K
7,873 sh × $37.80
Exec Apr 15 2025
Filed Apr 16 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $367K
8,201 sh × $44.70
Exec Mar 17 2025
Filed Mar 18 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $453K
9,100 sh × $49.79
Exec Feb 18 2025
Filed Feb 21 2025 · 5:30 PM ET † AKROSALE Akero Therapeutics, Inc. View filing → $2.7M
49,074 sh across 3 lots
Exec Jan 27 2025
Filed Jan 31 2025 · 5:30 PM ET † More filings →